â??An open label, single center, prospective clinical trial to assess the efficacy and safety of Safi Syrup manufactured by Hamdard Laboratories (INDIA) in the management of Acne Vulgaris.
- Conditions
- Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue
- Registration Number
- CTRI/2022/04/042147
- Lead Sponsor
- Hamdard Laboratories
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
1. Males and Females of age >=15and <=30 years suffering from mild to moderate symptoms of Acne Vulgaris (pimples).
2. Patient with signs of Acne Vulgaris.
3. Written informed consent signed by patient and willing to comply with the study procedure.
1.Males and Females of age <15 and >30 years.
2.Pregnant or lactating women.
3.Patients with other variants of acne like Acne fulminans, Acne rosacea and Acne necrotica.
4.Patients who had previous history of hypersensitivity to Ayush drugs.
5.Serious hepatic or renal insufficiencies
6.Patients on treatment with other antibiotics corticosteroids, retinoid, anticonvulsants and androgens in the preceding four weeks.
7.Patients who are taking any hormonal preparations e.g. oral contraceptive pills.
8.Patient participated in new drug evaluation program in preceding 3 months.
9.Patients with apparent physical or mental abnormalities.
10.Any other condition that in the opinion of the Investigator, does not justify the patientâ??s participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method